The strategy
A phased path to a validated claim.
Reach people first through a compliant men's health supplement, while clinical validation progresses toward a formal contraceptive claim — each stage funding the next.
The path
Validate
Early laboratory validation and HPLC standardisation of plant material. Lab and industry partnerships. Preliminary IP landscape work. Raising the friends-and-family round.
Early product
A men's health supplement with compliant structure/function claims — no contraceptive claim on the product, with the research made public. Nimboran fieldwork and partnership development.
Prove the claim
Clinical trials and regulatory engagement toward a validated contraceptive claim, funded in part by supplement revenue as the clinical pathway runs in parallel.
Extend, with integrity
Phytopharmaceutical and pharmaceutical pathways explored if needed for ethical production. Global-access pricing throughout.
Product strategy
Three tiers, one preparation.
The same plant supports a staged progression — from a wellness-positioned product that can reach people quickly, to a standardised extract with clinical backing, to a fully validated pharmaceutical pathway where it proves feasible and ethical.
Whole-plant supplement
Positioned around reproductive wellness with no direct contraceptive claims. US dietary-supplement pathway. Reaches people first.
Standardised extract
Concentrated, standardised extract with documented compound levels and clinical data backing contraceptive claims. Mainstream market, clinical-validation pathway — the same rigour required for a synthetic compound.
Full pharmaceutical
Potential isolated-compound or formulated product carrying direct contraceptive claims, pursued if warranted by demand and scale.
Global access
Premium markets fund reach.
Developed-market pricing subsidises discounted or at-cost access in regions where contraception is needed but unaffordable.